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Definition of Common Terms 
 
Performance: The system or application functions as designed and intended by developers 
and key stakeholders. 
Use: Logging into the BioSense 2.0 Web-based application to carry out specific surveillance 
tasks and functions.  
Utility: The degree to which BioSense 2.0 supports and adds value to existing surveillance 
capacity including (1) the ability to carry out surveillance tasks and functions; (2) achieve 
surveillance goals; and (3) integrate into existing workflow.    
Usability: The characteristics and qualities of the BioSense 2.0 Web-based application that 
support individuals’ ability to use the system effectively for their desired purposes. 
User: Any individual who registers and logs into the BioSense 2.0 Web-based application to 
carry out surveillance tasks.   
Partner: Any organization that has formally (through a cooperative agreement with CDC 
data sharing agreement or participation in governance activities) agreed to support the 
development and implementation of BioSense 2.0.    
Data Contributor: Any organization or entity that provides data to the BioSense 2.0 
system including hospitals, clinics, government agencies, or vendors.  
Onboarding Costs: The time, materials, and other resources expended to join the 
BioSense system, including both direct and indirect costs.  Not included are ongoing/use 





In 2003 the Centers for Disease Control and Prevention (CDC) launched BioSense 1.0 as a 
nationwide integrated system for early detection and assessment of bioterrorism-related 
illness that would receive automated data feeds from hospitals and medical facilities 
operated by the U.S. Department of Veterans Affairs (VA) and Department of Defense 
(DoD). In the years that followed, BioSense 1.0 added syndromic data from state health 
departments, anti-infective prescription data, and laboratory data from selected vendors. In 
June 2010 a 4-year effort, the BioSense Redesign project, was initiated to transform 
BioSense 1.0 to BioSense 2.0—an all-hazards surveillance system that would provide 
multipurpose value and timely data for regional and national public health situation 
awareness, routine public health practice, and health outcomes and public health 
improvement. 
Drawing upon 8 years of programmatic experience, stakeholder meetings, U.S. Senate’s 
input, General Accounting Office (GAO) reports, and a year of intensive user requirements 
gathering, the redesigned BioSense 2.0 aims to: 
 Incorporate state and local public health partners’ input into the BioSense Program 
design and governance. 
 Promote a proactive, collaborative, and transparent community. 
 Support the transmittal of syndromic surveillance data to meet Meaningful Use 
requirements. 
 Support an open, distributed computing model. 
 Improve the utility of the data/data sources. 
 Facilitate real-time interjurisdictional communication and collaboration. 
 Promote innovative epidemiological methods and practices. 
 Enhance the capacity of the public health workforce for surveillance practice. 
BioSense 2.0 represents a significant realignment of structure and governance from the 
previous system. Now in its third year, the BioSense Redesign has focused on coordinating 
efforts across multiple stakeholders [CDC, Association of State and Territorial Health 
Officers (ASTHO), National Association of County and City Health Officials (NACCHO), 
Council of State and Territorial Epidemiologists (CSTE)], and the International Society for 
Disease Surveillance (ISDS), enhancing program visibility and recognition, building local 
capacity through training and technical assistance, and supporting the expansion of 
BioSense 2.0 through targeted recruitment and onboarding activities. The BioSense 
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Redesign effort now requires a formative evaluation to ensure it is on track to achieve 
BioSense 2.0 aims. 
1.1 Purpose of the BioSense 2.0 Evaluation 
This BioSense 2.0 evaluation will assess the performance, use, utility, usability, and costs of 
the BioSense 2.0 system as well as the onboarding experience. The evaluation is intended 
to guide the BioSense 2.0 Governance Group, CDC, state, local, and territorial (STLT) 
stakeholders and the RTI BioSense Redesign team in their deliberations and decisions about 
the development of BioSense 2.0. The evaluation plan proposed here emphasizes process 
and short- and mid-term outcomes over long-term outcomes; it does not assess the overall 
impact or value of the program. However, this evaluation plan includes performance 
monitoring and cost measurement from which impact and longer-term outcomes can be 
evaluated. We have developed this plan in consideration of the following BioSense 2.0 Key 
Performance indicators: 
1. Increase the proportion of jurisdictions contributing data into BioSense 2.0 to 
improve the national picture of population health. 
2. Increase the percentage of public health agencies that can receive production 
syndromic surveillance Meaningful Use compliant messages from certified electronic 
health record (EHR) technology. 
The plan sets forth a logic model and the evaluation goals and questions; describes the 
various methods for addressing these questions; and includes reporting formats, a timeline, 
and next steps. 
In the remainder of the document we use the term “partner” to define those individuals or 
institutions that provide data to BioSense and also use the system. We use the more 
discrete term “user” when we refer specifically to those who use the system. 
1.2 BioSense 2.0 Logic Model 
Exhibit 1 specifies a logic model that describes the BioSense Program inputs, activities, and 
outcomes (short-, mid-, and long-term) for the BioSense 2.0 application. Performance 
measures that are linked to each short- and mid-term outcome in the logic model are 
presented in Appendix A. This logic model was developed in Option Year 1 of this contract 
collaboratively with the working group of the Technical Expert Panel (TEP). Members of that 
working group included Julia Gunn (Boston DOH), Richard Hopkins (Florida DOH), Dan Sosin 
(CDC), and Tom Chapel (CDC). The logic model is intended to be a dynamic representation 
of the program and should be continually refined and updated to capture the evolution of 
BioSense 2.0. 
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Exhibit 1. BioSense 2.0 Logic Model 
 
 
BioSense 2.0 will give users a flexible, user-friendly application with enhanced data that 
facilitates timely exchange of data across jurisdictions to support many surveillance needs 
(e.g., early detection, situation awareness, event response). A redesigned BioSense 2.0 will 
lead to greater and more diverse users with new skills and capacity to conduct routine and 
cutting-edge surveillance. Greater participation will lead to increased population coverage 
and provide a complete and robust (timely, representative, complete, reliable, and flexible) 
national view of the nation’s health in real time (Sosin, 2003). 
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2. OVERVIEW OF THE EVALUATION PLAN 
The Evaluation Plan of the BioSense 2.0 system is described in four sections: Section 2.1 
describes the evaluation approach; Section 2.2 presents goals and objectives for the 
evaluation; Section 2.3 presents evaluation questions and the methods we will employ to 
address them; Section 3 describes the proposed methods in detail; Section 4 presents the 
timeline for evaluation activities; and Appendix A includes the performance measures for 
short- and long-term outcomes. 
2.1 BioSense 2.0 Evaluation Approach 
The BioSense 2.0 evaluation approach shown in Exhibit 2 is based on CDC’s Framework 
Program Evaluation (http://www.cdc.gov/eval/framework/index.htm), and is intended to 
help BioSense stakeholders use and apply the evaluation findings to the fullest. The 
evaluation team, by involving end users from the onset, enables the evaluation to meet 
high standards for utility, feasibility, propriety, and accuracy. Thus, the engagement of 
BioSense 2.0 stakeholders early and throughout the evaluation is critical to the evaluation’s 
success. Accordingly, we will solicit the input and guidance of the ASTHO-led BioSense 2.0 
Governance Group to refine the evaluation design, instruments, and procedures; assess 
relevance and feasibility of this evaluation plan; and interpret and use evaluation findings. 
Exhibit 2. CDC Framework for Program Evaluation 
 
 
2.2 Evaluation Goals and Objectives 
For the public health workforce and others who are responsible for monitoring and securing 
the public’s health, a well-designed BioSense Program will enhance their capacity to detect, 
track, assess, and respond to health threats at the state, local, regional, and national levels. 
1. Identify and engage 
the intended users 
2. Describe the 
program
3. Focus the 
evaluation design
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The goals of this BioSense 2.0 evaluation plan and associated objectives are described 
below. Unless otherwise indicated, all objectives will be completed in Option Year 3.  
Goal Area 1: Performance Monitoring 
 Establish with the input of BioSense stakeholders a protocol (including performance 
measures, timing and frequency of reporting, sources of data, and reporting formats) 
for monitoring the performance of the BioSense 2.0 system in achieving short- and 
mid-term outcomes. To achieve this goal, the evaluation will: 
– Objective (1a): develop a performance monitoring template and protocol for the 
collection of data from the BioSense 2.0 application by June 1, 2013; 
– Objective (1b): establish a timeline for reporting performance measures collected 
in 1a by June 2013; and 
– Objective (1c): initiate the performance monitoring protocol by July 1, 2013. 
Goal Area 2: Use and Utility  
 Assess the types of users who are adopting BioSense 2.0 and the extent of their use.  
 Assess how BioSense 2.0 is being used and integrated into surveillance practice 
 Identify the STLT surveillance needs that BioSense 2.0 is meeting or supporting and 
assess how it is enhancing surveillance capacity. To achieve these goals, the 
evaluation will: 
– Objective (2a): review the results of the surveys conducted by the Governance 
Group and make recommendations for addressing the surveillance needs and 
issues raised by the respondents. 
Goal Area 3: Usability 
 Assess the usability of the BioSense 2.0 application. To achieve this goal, the 
evaluation will: 
– Objective (3a): administer the System Usability Scale (SUS) to all newly 
registered partners after 40 minutes of system use.1 
– Objective (3b): conduct qualitative usability testing sessions with 30-35 volunteer 
users and 11 Advance Panel users to gather open-ended feedback on what 
aspects of the interface and application work well or need to be modified.  
Goal Area 4: Onboarding Experiences and Participation 
 Assess the barriers and facilitators to BioSense 2.0 onboarding. To achieve this goal, 
the evaluation will: 
                                           
1 The Redesign Team estimated 40 minutes, based on their observations to date, as the amount of 
time a user needs with the system in order to be able to provide meaningful responses to the SUS 
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– Objective (4a): conduct six case studies by December 2013 to identify the 
technical, data quality, policy, program, workforce, and technical assistance 
factors that impede or facilitate BioSense 2.0 enrollment and onboarding. 
Goal Area 5: Onboarding Costs 
 Develop cost estimates for onboarding that will help jurisdictions with BioSense 2.0 
adoption and planning. 
 Assess the feasibility of systematically collecting cost data at the jurisdictional level 
to support future cost-benefit studies. 
 Assess the benefits of BioSense 2.0 in helping jurisdictions meet Meaningful Use 
requirements for syndromic surveillance. 
 Assess the benefits of BioSense 2.0 in cross-jurisdictional data exchange. To achieve 
these goals, the evaluation will: 
– Objective (5a): conduct six case studies by August 2013 to monetize cost 
burdens (and savings) incurred by state, local, and regional BioSense 2.0 
participants. 
2.3 Evaluation Design 
To achieve the evaluation plan’s goals and objectives, we propose a mixed-method design 
consisting of five methods: (1) performance measurement using analytic data from the 
BioSense 2.0 application and secondary datasets; (2) surveys conducted by ASTHO on 
behalf of the Governance Group; (3)  usability testing and assessments with BioSense 
users; (4) case studies of current BioSense 2.0 participants onboarding experiences; and 
(5) case studies of BioSense 2.0 onboarding costs. The first three methods, performance 
monitoring, surveys and usability testing will examine whether BioSense 2.0 is performing 
as intended and is meeting users’ needs. Performance monitoring also fulfills information 
requests needed to comply with GAO investigations of BioSense 2.0 performance. Case 
studies will gather insights from qualitative data (i.e., focus groups and key informant 
interviews) that cannot be obtained through BioSense 2.0 data or application analytics. The 
cost analysis captures the economic burden of BioSense 2.0 participation for STLT 
participants. This information can be used to make the business case for BioSense 2.0 
participation and/or alert CDC and the Governance Group to critical cost barriers they must 
address to meet recruitment targets. 
Exhibit 3 summarizes the design of the BioSense 2.0 evaluation and its discrete 
components: the evaluation questions (organized by goal areas), methods, and data 
sources and the relationships among them. 
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Exhibit 3. BioSense 2.0 Evaluation Questions, Methods, and Data Sources 








Goal Area 1: Performance Monitoring     
Does BioSense 2.0 enhance the number 
and diversity of surveillance data relative 
to BioSense 1.0? 
Performance 
monitoring 
   
Do BioSense 2.0 data meet the criteria for 
quality (flexibility, timeliness, 




   
Is BioSense 2.0 use increasing over time?  Performance 
monitoring 
   
Do training and technical assistance 
enhance workforce competency to use 
BioSense 2.0?  
Performance 
monitoring  
   
To what extent is BioSense 2.0 supporting 




   
Does BioSense 2.0 provide a national 
surveillance view?  
Performance 
monitoring  
   
How complete and representative is the 
population covered by BioSense 2.0?  
Performance 
monitoring  
   
Goal Area 2: Use and Utility 
Who is using BioSense 2.0 and what is the 
extent of their use?  




   
How is BioSense 2.0 supporting and 
enhancing STLT surveillance capacity? 
ASTHO 
survey 
   
Goal Area 3: Usability     




   
Goal Area 4: Onboarding Experience     
What are the technical barriers and 
facilitators to BioSense 2.0 participation?  
Case study     
What are the policy barriers and 
facilitators to BioSense 2.0 participation? 
Case study     
What are the programmatic barriers and 
facilitators to BioSense 2.0 participation? 
Case study     
What are the workforce barriers and 
facilitators to BioSense 2.0 participation? 
Case study     
How satisfactory and effective is 
onboarding technical assistance and how 
could it be improved? 
Case study     
How could the barriers identified be 
addressed?  
Case study    
(continued) 
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Exhibit 3. BioSense 2.0 Evaluation Questions, Methods, and Data Sources 
(continued) 








Goal Area 5: Onboarding Costs     
What are the adoption costs for using 
BioSense 2.0? 
Case study    
What are the participants’ ongoing costs of 
using BioSense 2.0? 
Case study    
What factors influence costs of adoption 
and maintenance?  
Case study    
What are the benefits of BioSense 
participation in preparing jurisdictions to 
accept Meaningful Use data or syndromic 
surveillance?  
Case study    
What are the benefits of BioSense 2.0 in 
cross-jurisdictional data exchange?  
Case study    
* Data derived from the BioSense application. 
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3. METHODS 
3.1 Performance Monitoring 
The performance monitoring protocol that the evaluation establishes will track the 
program’s achievement of short- and mid-term outcomes as specified in the BioSense 2.0 
logic model on an ongoing basis. Appendix A lists a preliminary set of performance 
measures mapped to these short- and mid-term outcomes. Performance monitoring will 
provide timely feedback about application performance and use; identify the application’s 
strengths and deficiencies; and inform decisions regarding application development and 
enhancement. 
We will work with CDC to create a reporting template to capture performance measures at 
the appropriate level of detail with clear and concise definitions for calculation of the 
measures. We will establish a protocol for: 
 the reporting frequency of each measure (some may be need to be reported less or 
more often than others); 
 the key entities responsible for preparing and submitting the performance monitoring 
reports; and 
 entities within CDC, the Governance Group, and others who should receive and 
review the reports. 
Using the TEP-approved logic model as a guide, in Option Year 2 we identified and 
developed a set of new draft performance measures for each short- and mid-term outcome 
(see Exhibit 4). 
Exhibit 4. BioSense 2.0 Outcomes 
Short-Term Outcomes Mid-Term Outcomes 
New data/Additional data Increased BioSense 2.0 use  
High-quality data (timely, flexible, complete, 
reliable) 
Cross-jurisdictional data exchange 
User-friendly experience Greater diversity of users 
Enhanced workforce competency to use the 
application 
National surveillance views 
Increased BioSense participation Complete and representative population coverage 
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The development of the measures will proceed in stages as follows with input from CDC, the 
Governance Group, and the Federal Opportunity Announcement (FOA) grantees at each 
step: 
1. Initial mapping of outcomes to candidate measures with the TEP (completed); 
2. Systematic review of each candidate measure for validity, feasibility, relevance, and 
utility (in progress); 
3. Assessment of the appropriate reporting period (monthly, quarterly, annual) and 
presentation format for each measure; 
4. Development of a reporting template and protocol for dissemination and review; and 
5. Final vetting, selection and refinement of the measures and reporting protocol. 
3.2 Surveys of BioSense Use and Utility 
Since its inception, the BioSense Program has had an interest in examining the application’s 
use (e.g., how many users, what features do they use and how often) and utility (e.g. how 
well BioSense supports surveillance capacity, complements workflow, adds value), and CDC 
has documented and disseminated success stories through the CDC’s BioSense Web site. 
However, the findings from BioSense 2.0 requirement-gathering activities (conducted in 
Years 1 and 2 of the BioSense Redesign) found that jurisdictions had many concerns about 
BioSense 2.0 and syndromic surveillance more generally. The Redesign team considered 
these concerns in developing BioSense 2, but periodic feedback from partners is needed to 
ensure that it is meeting surveillance needs as they evolve. 
In late 2012 ASTHO administered a Web-based survey of BioSense partners on behalf of the 
BioSense 2.0 Governance Group to assess their use of BioSense. In addition, a second 
survey to assess user functionality needs was deployed in April 2013. The results of these 
surveys complement the evaluation’s goals and address a number of key evaluation 
questions as noted in Exhibit 3. The evaluation team proposes to review the results and 
recommend changes and enhancements to BioSense 2.0 to address user needs.  
In addition, the evaluation team proposes to work with the Governance Group to plan 
additional survey data collection to assess aspects not currently captured through existing 
surveys, including preferred algorithms, functions and features, workflow integration, and 
value.  
3.3 Usability Testing 
Usability testing assures that the graphical interface (e.g., formatting, spacing, button 
placement, and other design factors) of the BioSense 2.0 Web-based application facilitates 
access to its features and supports the individual’s ability to use the system effectively. The 
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BioSense Redesign team has regularly engaged public health practitioners to assess the 
usability of BioSense 2.0 since the inception of the project. 
We have used several methods to assess usability including remote and on-site testing with 
individuals and groups of participants; an Advanced User Panel of 11 volunteers who are 
expert in syndromic surveillance; and the System Usability Scale, a standardized survey 
instrument to measure individuals’ comfort with the BioSense 2.0 interface. The most recent 
results of these activities are detailed in two reports prepared for CDC and were used to 
guide the development and refinement of the BioSense 2.0 graphical interface (Pina, 
Recker, Chester, & Massoudi, 2013; Pina, Recker, Chester, & Massoudi, 2012). 
Evaluation of usability can be achieved through continued Web-based administration of the 
SUS  to all users once they have logged a minimum of 40 minutes in the application. Our 
monitoring of usage patterns indicate that most users log in for short periods of time (3 
minutes or less), so waiting until they have sufficient experience with the system will allow 
them to provide more complete feedback. The SUS results will be incorporated into the 
performance monitoring protocol and the aggregate scores and trends reported along with 
other performance measures.  Also, we will gather qualitative feedback on usability through 
remote and in-person usability testing with 30-35 volunteer users at various venues such as 
conferences and workshops.   
3.4 Case Studies of BioSense 2.0 Onboarding Experiences and 
Participation 
The purpose of the case studies is to identify the barriers in STLT jurisdictions that hinder 
participation in BioSense 2.0 or obstacles they encounter during onboarding. These case 
studies will also explore the factors that facilitate the decision to join BioSense 2.0 and 
proceed through onboarding quickly and easily. An understanding of these participation 
barriers and facilitators will inform current efforts to recruit and engage STLT jurisdictions 
and establish a coordinated and responsive onboarding process. These case studies will also 
inform best practices and standard operating procedures to prepare a jurisdiction for 
onboarding and facilitate a timely and efficient experience. The ability of BioSense 2.0 to 
achieve national coverage hinges largely on the effectiveness of recruitment and onboarding 
and data sharing; therefore, these efforts are extremely important at this stage of BioSense 
2.0 Program development. 
Case Study Selection. Onboarding barriers and facilitators will be captured in nine case 
studies. To capture the fullest possible range of barriers and facilitators within the relatively 
small pool of cases, we have limited selection to three criteria. These criteria represent the 
predominant models of entry, and we view them as the most critical in determining the 
onboarding effort: 
BioSense 2.0 Evaluation Plan  
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 One-offs (jurisdictions bringing in hospitals one by one); 
 Existence of a syndromic surveillance system; and 
 Existence of a health information exchange (HIE). 
We have selected two jurisdictions to represent each onboarding criterion (see Exhibit 5) to 
allow for comparison. The jurisdictions we selected have either completed or will have 
completed onboarding by the time of data collection. For each criterion, we will also include 
a jurisdiction that has opted not to participate.  We would welcome additional feedback from 
stakeholders regarding other possible jurisdictions to include.   We define completion of 
onboarding as having submitted at least one data feed or all the targeted feeds for a given 
state or jurisdiction, depending on the model of onboarding.  
Exhibit 5. Preliminary Jurisdictions Identified for Onboarding Case Studies 
Model Case 
One-offs  Montana, Nevada, TBD non participant 
State-based HIE-system  Kansas, West Virginia, TBD non participant 
Existing syndromic surveillance system  TBD (2 participant, 1 non participant)  
 
Data Collection. Data collection will consist of key informant interviews with individuals 
involved in onboarding activities. The interviews will take place in person during a 1-day site 
visit or if the informant is unavailable during the site visit, the interview will take place by 
phone. If participants have similar roles and responsibilities, we may conduct a group 
interview. Each interview will last approximately 60 minutes. We will record the interviews, 
with the permission of the participants, to ensure accurate note taking and transcription. 
During interviews, we will assess the following broad categories of barriers and facilitators: 
 Technical barriers/facilitators—attributes of the existing systems, attributes of 
the uploading data and requesting data from other jurisdictions; 
 Data quality barriers/facilitators—data quality concerns regarding timeliness, 
flexibility, completeness, reliability, representativeness; 
 Policy barriers/facilitators—political support, development of new policies and 
procedures, processing data sharing agreements, and coordinating with the BioSense 
2.0 community (e.g., CDC), hospitals; 
 Programmatic barriers and facilitators—support from leadership, state and local 
relationships, available and dedicated resources, value proposition for BioSense 2.0 
and/or syndromic surveillance, perceived needs and benefits; 
 Workforce barriers and facilitators—training, skills and competencies; and 
BioSense 2.0 Evaluation Plan 
13 
 Technical assistance—aspects of technical assistance during onboarding worked 
well and did not, what should be changed or improved. 
Data Analysis. We will emphasize examination of the themes in the six categories listed 
above that facilitate or impede onboarding efforts. We will qualitatively analyze data using a 
set of a priori codes within each category and then compare the coding results within and 
across models to identify patterns. We will also develop new codes as they emerge from the 
data. 
3.5 Case Studies of BioSense 2.0 Onboarding Costs 
The purpose of the onboarding cost study is to monetize the cost burdens (and cost 
savings) that state, local, and regional BioSense 2.0 participants incur. We will assess both 
the hard costs (cash outlays) and the soft costs (utilization of resources such as labor effort) 
of participation in the BioSense 2.0 community. We will collect data on adoption costs and 
ongoing costs from the existing BioSense 2.0 participants. We will also examine the benefits 
of participation, focusing on how BioSense 2.0 facilitates compliance with Meaningful Use 
requirements which begin October 1, 2013. 
Finally, we will assess the feasibility of collecting data systematically from BioSense 2.0 
participants to monitor and track the costs over time to conduct cost-benefit analyses and 
estimate ROI. 
Case Study Selection. We anticipate in-depth cost data collection from six STLT 
participants. We selected jurisdictions based on criteria that we hypothesize will affect 
BioSense 2.0 adoption costs. These selection criteria include 
 jurisdiction type (city, state, regional, local); 
 degree of urbanization 
 years of experience with biosurveillance; and 
 existence of an HIE. 
Based on these characteristics we identified three cost models and selected two jurisdictions 
to represent each model (see Exhibit 6). Selected jurisdictions have either completed or 
will have completed onboarding by the time of data collection. As with the onboarding case 
studies, we would engage stakeholders in the final selection of jurisdictions.  We use the 
same definition for onboarding as for the onboarding case studies. 
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Exhibit 6. Preliminary Jurisdictions Identified for Case Studies of Onboarding 
Costs 
Cost Model Case 
Large city Boston, Denver 
State-based HIE-system  Kansas, West Virginia 
Minimal experience w/syndromic surveillance Alabama, Montana 
 
Because of the small pool of jurisdictions that meet the criteria for the onboarding-cost and 
onboarding experience case studies, three jurisdictions will be included in both sets of case 
studies. We have assembled a cross-case staffing to ensure efforts are coordinated and that 
overlapping research and data collection are mutually beneficial and increase efficiency, 
while not overburdening stakeholders with data requests. 
Case Study Data Collection. Primary data collection will be necessary to quantify 
economic benefits and costs. We will leverage existing BioSense 2.0 knowledge resources, 
including environmental scans, usage data, and reported statistics to minimize users’ 
burden for participating in the evaluation. Data collection will consist of key informant 
interviews with individuals involved in the onboarding activities and a short pre-interview 
questionnaire. The interviews will take place in person during a 1-day site visit or if the 
informant is unavailable during the site visit, the interview will take place by phone. If 
participants have similar roles and responsibilities, we may conduct a group interview. Each 
interview will last about 60 minutes. Informants who are also participating in the 
onboarding experience case study will have longer interviews—about 90 minutes. The 
interviews will be recorded, with participants’ permission, to ensure accurate note taking. 
During interviews, we will assess BioSense 2.0 costs in the following broad categories: 
 adoption costs—developing new policies and procedures, processing data sharing 
agreements, and coordinating with the BioSense 2.0 community (e.g., CDC). 
 ongoing costs—uploading data and requesting data from other jurisdictions. 
 Meaningful Use benefits—using BioSense 2.0 to comply with Meaningful Use 
compared to an alternative method. 
 Data sharing benefits—finding out how often, how, and from whom jurisdiction 
requested data pre and post BioSense 2.0. 
Data Analysis. We will emphasize estimating the costs of participation in the BioSense 2.0 
community—labor, capital, and services spending—including adoption costs and ongoing 
costs. For jurisdictions who were onboarded recently, we may need to estimate the ongoing 
costs as opposed to calculating them based on actual spending. We will develop six 
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estimates that will provide a proxy for the costs of BioSense 2.0 usage based on the cost 
model. We will estimate these costs as well as the time period over which they accrued. For 
advanced users, we will also seek to ascertain previous spending levels on labor as well as 
capital on existing syndromic surveillance programs. 
Although the case study will focus on costs, we will examine two key benefits of 
participation: compliance with Meaningful Use requirements and easier access to 
surveillance data from other jurisdictions. For each jurisdiction we will quantitatively 
estimate the costs to comply with Meaningful Use Stage 2 without BioSense 2.0—that is, 
adoption of an alternate solution and subsequent ongoing costs—and we will compare them 
to the costs for BioSense 2.0. Assuming that BioSense 2.0 is less expensive, our analysis 
and findings will present the difference as cost savings or cost minimizing. 
We will qualitatively assess the benefits of data sharing by examining the cost savings of 
more easily and quickly seeing trends inside and outside of the jurisdiction. This exploratory 
analysis of benefits could be used as input in a future, more comprehensive analysis of the 
private and social benefits of BioSense 2.0. 
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4. REPORTING 
4.1 Structure, Format, and Dissemination 
We will tailor the structure, format, and dissemination of the evaluation findings to achieve 
maximum utility for a diverse BioSense 2.0 stakeholder audience including: 
 A concise Performance Monitoring Report template with appropriate visualizations 
that allow readers to clearly understand trends, gaps, and areas for improvement. 
 Six short, 2–4-page Evaluation Briefs that highlight the findings from the onboarding 
experience case studies, with each brief devoted to the six categories of barriers and 
facilitators (technical, data quality, policy, program, workforce, technical assistance). 
 One 4–6-page Evaluation Brief that synthesizes findings from multiple methods (case 
studies, Governance surveys, performance monitoring) and focuses on BioSense 2.0 
use, utility, and usability. 
 A 15–20-page Onboarding Cost Case Study Report that includes a summary of the 
data collection methodology, discussion of the costs calculated, and additional 
qualitative results from the interviews. The report will also present the cost savings 
to CDC of BioSense 2.0 and recommend how data on the costs of participation in 
BioSense 2.0 may be collected, calculated, and reported moving forward. 
The format of each product will be designed to meet the information needs of specific 
stakeholders. The Performance Monitoring Report will be concise so CDC and the BioSense 
Redesign team can review it quickly on a monthly basis (or less frequently for some 
measures) and discuss it as needed during routine project meetings. The format of the 
reports will lend themselves to broader dissemination to other audiences such as CDC 
leadership or the Governance Group. 
The brief format (Evaluation Brief) for the findings is targeted to public health officials who 
need programmatic information that can be applied to practice. The BioSense Redesign 
team will work with communication specialists to ensure that the design, tone, and style of 
the brief appeals to public health audiences. The brief format is also well suited for posting 
on CDC and the BioSense Redesign Collaboration Web Site and for distribution at meetings 
and conferences. We will facilitate these broader dissemination goals by ensuring all briefs 
are 508 compliant. We will submit drafts of briefs to CDC for approval before distribution. 
The Onboarding Cost Case Study Report is intended for CDC program management and 
provides more detail and background necessary for weighing the significance of the 
recommendations in the report. The topic of the report itself, cost estimation of surveillance 
use, itself may be of interest to peer-reviewed journals. The structure and detail of the 
report will facilitate conversion to manuscript form.  
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5. TIMELINE 
Exhibit 7 presents our project schedule contingent upon receiving CDC approval to begin 
evaluation activities. We assume a start date of  March, 2013. 
Exhibit 7. Proposed Evaluation Schedule 
Description Due Date 
Presentation of Evaluation Plan to Governance Group March 2013 
Case Study Selection  March 2013 
Pilot Case Study Site Visit May 2013 
Vetting of Draft Performance Measures March–May 2013 
Draft Performance Monitoring Template and Protocol  May 2013 
Final Performance Monitoring Template and Protocol  June 2013 
Case Study Site Visits June–August 2013  
Draft Case Study Briefs  September-October 2013 
Final Case Study Briefs November 2013 
Draft Cost Report September 2013 
Final Cost Report October 2013 
 
Performance measures are intended to evolve with the changing needs of BioSense 2.0, and 
this flexible development cycle allows new measures to be added or existing ones modified 
or dropped based on stakeholder input. Additional CDC/stakeholder input into the selection, 
refinement, and presentation of the draft set of performance measures is needed to achieve 
the goals specified above.  
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6. NEXT STEPS 
The evaluation plan is intended to reflect the needs of BioSense 2.0 stakeholders (CDC, 
Governance Group, STLT partners, FOA grantees,) and evolve with the changing needs of 
the program by adding or dropping goals, questions, and measures based on stakeholder 
input. Additional stakeholder input is necessary to move this proposed plan forward. Initially 
the plan will be presented to the Governance Group in March 2013. Additional input from 
stakeholders can be obtained in various ways by meeting with stakeholder groups 
individually to review all or pieces of the plan. Ideally, an evaluation workgroup would be 
convened with members representing the range of stakeholders who would meet 
periodically to review, advise, and set the direction of the evaluation. We will work with CDC 
and the Governance Group in the remainder of Option Year 2 to establish the best strategy 
for engaging stakeholders. 
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BIOSENSE 2.0 PERFORMANCE MEASURES 
Short-Term and Mid-
Term Outcomes Measurement Data Source 
Reporting 
Timeframe 
Short-Term Outcomes    









 Number and percentage of 









High-quality data  Percentage of queries with 
multiple syndromes and 
user-defined syndromes 
(flexibility)  
Application analytics Monthly 
 Percentage of data received 
on time (timeliness) 
Application analytics Monthly 
 Percentage of data with 
missing fields 
(completeness) 
Application analytics Monthly 
 Percentage of data with 
inconsistent entries 
(reliability)  
Application analytics Monthly 
User-friendly 
experience  
Average number of minutes 
from first login to first 
query 
Application analytics Monthly 
 System Usability Scale 
scores 
System Usability Scale 
survey 
Biannually  
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Short-Term and Mid-




competency to use the 
application 
Total percentage of and 










Application analytics Monthly 
Increased BioSense 2.0 
participation  
Number of jurisdictions 
contributing data 




Increased capacity to 
receive SS Meaningful 
Use compliant 
messages 
Percentage of jurisdictions 
that can receive SS 
Meaningful Use compliant 
messages from EHR 
technology. 
 Monthly 
Mid-Term Outcomes    
    
Increased BioSense 2.0 
use  
Number of distinct users A 
Number of logins A 
Application session time in 
minutes A 
Number of records 
transmitted A 
Mean number of queries 
per user 
Application analytics Monthly 
 Number of queries during a 
public health event 
Application analytics As needed 
    
Increased exchange of 
data among 
jurisdictions 
Number of jurisdictions 
electing to share data 
Application analytics Semi-annually 
 Number of comments  Application analytics Semi-annually 
 Number of shared views Application analytics Semi-annually 
 Number of local and 
regional surveillance 
exchange hubs or networks 
  
Greater diversity of 
users 
Percentage of users: 
by occupation 
by organizational affiliation 
Application analytics Annually 
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Short-Term and Mid-









Application analytics Monthly 
 Percentage of facilities 
providing data: (ED, A 
hospitals, clinics) 




Percentage of U.S. ED visits 






 Percentage of the U.S. 
population covered by 
BioSense 2.0 hospitals 
Population census 
 
NCHS hospital discharge 
data 
Annually 
 Percentage of U.S. 
population in jurisdictions 
with BioSense 2.0 DUA  
Population census 
 
BioSense Program  
 
A=current performance measure 
